These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7526536)

  • 1. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.
    Christensen ND; Kirnbauer R; Schiller JT; Ghim SJ; Schlegel R; Jenson AB; Kreider JW
    Virology; 1994 Nov; 205(1):329-35. PubMed ID: 7526536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
    Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
    Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types.
    Christensen ND; Cladel NM; Reed CA; Budgeon LR; Embers ME; Skulsky DM; McClements WL; Ludmerer SW; Jansen KU
    Virology; 2001 Dec; 291(2):324-34. PubMed ID: 11878901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of neutralizing antibodies to papillomaviruses by anti-idiotypic antibodies.
    Christensen ND; Reed CA; Cladel NM
    Virology; 1995 Jul; 210(2):292-301. PubMed ID: 7542415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
    Xu Y; Wang Q; Han Y; Song G; Xu X
    J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.
    Roth SD; Sapp M; Streeck RE; Selinka HC
    Virol J; 2006 Oct; 3():83. PubMed ID: 17014700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
    Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
    Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunogenicity study of HPV 6b virus-like particles].
    Liu Y; Liu X; Frazer IH
    Zhonghua Yi Xue Za Zhi; 2002 May; 82(9):587-9. PubMed ID: 12133476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer.
    Brown DR; Bryan JT; Schroeder JM; Robinson TS; Fife KH; Wheeler CM; Barr E; Smith PR; Chiacchierini L; DiCello A; Jansen KU
    J Infect Dis; 2001 Nov; 184(9):1183-6. PubMed ID: 11598842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay].
    Lu WX; Cheng T; Li SW; Pan HR; Shen WT; Chen YX; Zhang T; Zheng Z; Zhang J; Xia NS
    Sheng Wu Gong Cheng Xue Bao; 2006 Nov; 22(6):990-5. PubMed ID: 17168325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
    Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
    Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
    Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
    J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA.
    Rommel O; Dillner J; Fligge C; Bergsdorf C; Wang X; Selinka HC; Sapp M
    J Med Virol; 2005 Jan; 75(1):114-21. PubMed ID: 15543569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papillomavirus-like particles and HPV vaccine development.
    Schiller JT; Lowy DR
    Semin Cancer Biol; 1996 Dec; 7(6):373-82. PubMed ID: 9284529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.
    Christensen ND; Dillner J; Eklund C; Carter JJ; Wipf GC; Reed CA; Cladel NM; Galloway DA
    Virology; 1996 Sep; 223(1):174-84. PubMed ID: 8806551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological analyses of human papillomavirus capsids.
    Giroglou T; Sapp M; Lane C; Fligge C; Christensen ND; Streeck RE; Rose RC
    Vaccine; 2001 Feb; 19(13-14):1783-93. PubMed ID: 11166904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
    Combita AL; Touzé A; Bousarghin L; Christensen ND; Coursaget P
    J Virol; 2002 Jul; 76(13):6480-6. PubMed ID: 12050360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.
    Yeager MD; Aste-Amezaga M; Brown DR; Martin MM; Shah MJ; Cook JC; Christensen ND; Ackerson C; Lowe RS; Smith JF; Keller P; Jansen KU
    Virology; 2000 Dec; 278(2):570-7. PubMed ID: 11118379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.